BRPI0406745A - Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico - Google Patents
Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmicoInfo
- Publication number
- BRPI0406745A BRPI0406745A BR0406745-2A BRPI0406745A BRPI0406745A BR PI0406745 A BRPI0406745 A BR PI0406745A BR PI0406745 A BRPI0406745 A BR PI0406745A BR PI0406745 A BRPI0406745 A BR PI0406745A
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- amino acids
- consecutive amino
- sequence
- systemic lupus
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 239000008137 solubility enhancer Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003172 anti-dna Effects 0.000 abstract 1
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
"FORMULAçõES PARENTERAIS DE PEPTìDEOS PARA O TRATAMENTO DE LUPUS ERITEMATOSO SISTêMICO". A presente invenção provê uma composição farmacêutica compreendendo: um veículo aquoso; de 0,1 mg/ml a 20 mg/ml da composição de um sal farmaceuticamente aceitável de a) peptídeo compreendendo pelo menos 12 e no máximo 30 aminoácidos consecutivos possuindo uma seq³ência correspondendo a (i) uma seq³ência de aminoácidos encontradas dentro de uma região determinante de complementaridade (CDR) de uma cadeia leve ou pesada de um anticorpo 16/6 Id de anti-DNA monoclonal humano que induz uma resposta à doença tipo lupus eritematoso sistêmico (SLE) em camundongo, ou b) um peptídeo compreendendo aminoácidos consecutivos possuindo a seq³ência mostrada por qualquer das SEQ ID NOS. 8-17, ou c) um peptídeo compreendendo aminoácidos consecutivos possuindo uma seq³ência de qualquer de e b) , ou pelo menos duas das seq³ências em (a) (1), (a) (ii) e (b) (i) a (b) (x), ou d) um peptídeo compreendendo aminoácidos consecutivos possuindo uma seq³ência compreendendo pelo menos duas seq³ências idênticas incluídas em (a) (i) , (a) (ii) e (b) (i) a (b) (x) ; e um intensificador de solubilidade, em que tanto o peptídeo quanto o intensificador de solubilidade são dissolvidos no veículo aquoso; e em que a composição possui um pH entre 4 e 9, e um método de alívio de sintomas de SLE em humanos pela administração de uma quantidade eficaz da composição.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43991803P | 2003-01-14 | 2003-01-14 | |
| PCT/US2004/000948 WO2004064787A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0406745A true BRPI0406745A (pt) | 2005-12-20 |
Family
ID=32771757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0406745-2A BRPI0406745A (pt) | 2003-01-14 | 2004-01-14 | Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20050008634A1 (pt) |
| EP (1) | EP1594434B1 (pt) |
| JP (2) | JP4817068B2 (pt) |
| KR (1) | KR20050100617A (pt) |
| CN (1) | CN1774259B (pt) |
| AU (1) | AU2004206842A1 (pt) |
| BR (1) | BRPI0406745A (pt) |
| CA (1) | CA2513320C (pt) |
| CO (1) | CO5640143A2 (pt) |
| CR (1) | CR7938A (pt) |
| DK (1) | DK1594434T3 (pt) |
| EA (1) | EA009123B1 (pt) |
| EC (1) | ECSP055961A (pt) |
| ES (1) | ES2606464T3 (pt) |
| IL (1) | IL169574A (pt) |
| IS (1) | IS7972A (pt) |
| MX (1) | MXPA05007549A (pt) |
| NO (1) | NO20053773L (pt) |
| NZ (1) | NZ541658A (pt) |
| WO (1) | WO2004064787A2 (pt) |
| ZA (1) | ZA200506206B (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US20050008634A1 (en) * | 2003-01-14 | 2005-01-13 | Sharon Cohen-Vered | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| UA83816C2 (ru) * | 2003-01-14 | 2008-08-26 | Тева Фармасьютикал Индастриз, Лтд | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| AR074357A1 (es) * | 2008-11-17 | 2011-01-12 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas. metodo de dialisis in vitro |
| WO2013123254A1 (en) | 2012-02-15 | 2013-08-22 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| CN104470500A (zh) * | 2012-07-12 | 2015-03-25 | 赛诺菲 | 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物 |
| HK1213585A1 (zh) | 2012-10-22 | 2016-07-08 | Cydex Pharmaceuticals, Inc. | 烷基化环糊精组合物及其制备和使用方法 |
| WO2014193611A1 (en) * | 2013-05-29 | 2014-12-04 | Oklahoma Medical Research Foundation | Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity |
| US10189881B2 (en) | 2013-07-26 | 2019-01-29 | The Regents Of The University Of California | MPS peptides and use thereof |
| US10314889B2 (en) * | 2013-12-20 | 2019-06-11 | The Regents Of The University Of California | Suppression of allergic lung inflammation and hyperreactivity |
| EP3183295B1 (en) | 2014-08-22 | 2023-08-02 | CyDex Pharmaceuticals, Inc. | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same |
| IL299759A (en) | 2015-12-30 | 2023-03-01 | Genentech Inc | Formulations with reduced polysorbate dissolution |
| TWI797073B (zh) | 2016-01-25 | 2023-04-01 | 德商安美基研究（慕尼黑）公司 | 包含雙特異性抗體建構物之醫藥組合物 |
| AU2018205885A1 (en) * | 2017-01-05 | 2019-06-27 | Yeda Research And Development Co. Ltd. | Peptides for treating Sjogren's syndrome |
| EP3608615A4 (en) * | 2017-04-04 | 2021-01-20 | Nitto Denko Corporation | LYOPHILIZED BODY MANUFACTURING PROCESS AND ITS MANUFACTURING DEVICE |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| CN111683654A (zh) * | 2017-11-30 | 2020-09-18 | 细胞凝胶制药有限责任公司 | 新型镇痛药物制剂及其用途 |
| CN112143707A (zh) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | 一种治疗自身免疫细胞的免疫细胞及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60184098A (ja) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | 新規なペプチド及びこれを有効成分とする利尿剤 |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5126249A (en) * | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| US6613536B1 (en) * | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| IL120503A0 (en) * | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| US20020054872A1 (en) * | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| SE9802938D0 (sv) * | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US20050008634A1 (en) * | 2003-01-14 | 2005-01-13 | Sharon Cohen-Vered | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| UA83816C2 (ru) * | 2003-01-14 | 2008-08-26 | Тева Фармасьютикал Индастриз, Лтд | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ |
| US7018891B2 (en) * | 2003-12-16 | 2006-03-28 | International Business Machines Corporation | Ultra-thin Si channel CMOS with improved series resistance |
-
2004
- 2004-01-14 US US10/758,397 patent/US20050008634A1/en not_active Abandoned
- 2004-01-14 EA EA200501131A patent/EA009123B1/ru not_active IP Right Cessation
- 2004-01-14 WO PCT/US2004/000948 patent/WO2004064787A2/en not_active Ceased
- 2004-01-14 NZ NZ541658A patent/NZ541658A/en unknown
- 2004-01-14 CN CN2004800069872A patent/CN1774259B/zh not_active Expired - Lifetime
- 2004-01-14 EP EP04702215.7A patent/EP1594434B1/en not_active Expired - Lifetime
- 2004-01-14 BR BR0406745-2A patent/BRPI0406745A/pt not_active IP Right Cessation
- 2004-01-14 JP JP2006500956A patent/JP4817068B2/ja not_active Expired - Fee Related
- 2004-01-14 MX MXPA05007549A patent/MXPA05007549A/es not_active Application Discontinuation
- 2004-01-14 CA CA2513320A patent/CA2513320C/en not_active Expired - Lifetime
- 2004-01-14 AU AU2004206842A patent/AU2004206842A1/en not_active Abandoned
- 2004-01-14 KR KR1020057013098A patent/KR20050100617A/ko not_active Withdrawn
- 2004-01-14 DK DK04702215.7T patent/DK1594434T3/da active
- 2004-01-14 ES ES04702215.7T patent/ES2606464T3/es not_active Expired - Lifetime
-
2005
- 2005-07-06 IL IL169574A patent/IL169574A/en active IP Right Grant
- 2005-08-03 ZA ZA200506206A patent/ZA200506206B/en unknown
- 2005-08-05 IS IS7972A patent/IS7972A/is unknown
- 2005-08-08 NO NO20053773A patent/NO20053773L/no not_active Application Discontinuation
- 2005-08-09 CR CR7938A patent/CR7938A/es not_active Application Discontinuation
- 2005-08-10 CO CO05079328A patent/CO5640143A2/es not_active Application Discontinuation
- 2005-08-11 EC EC2005005961A patent/ECSP055961A/es unknown
-
2008
- 2008-11-10 US US12/291,439 patent/US20090169559A1/en not_active Abandoned
-
2011
- 2011-03-24 JP JP2011066343A patent/JP2011173888A/ja active Pending
-
2012
- 2012-04-23 US US13/453,979 patent/US20130023485A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1774259A (zh) | 2006-05-17 |
| JP2011173888A (ja) | 2011-09-08 |
| WO2004064787A3 (en) | 2005-12-15 |
| JP4817068B2 (ja) | 2011-11-16 |
| IS7972A (is) | 2006-07-15 |
| CA2513320C (en) | 2018-03-27 |
| CA2513320A1 (en) | 2004-08-05 |
| WO2004064787A2 (en) | 2004-08-05 |
| NZ541658A (en) | 2008-04-30 |
| ZA200506206B (en) | 2006-12-27 |
| CN1774259B (zh) | 2011-12-28 |
| ES2606464T3 (es) | 2017-03-24 |
| CO5640143A2 (es) | 2006-05-31 |
| DK1594434T3 (da) | 2017-01-02 |
| EP1594434A2 (en) | 2005-11-16 |
| KR20050100617A (ko) | 2005-10-19 |
| IL169574A (en) | 2015-08-31 |
| IL169574A0 (en) | 2007-07-04 |
| NO20053773L (no) | 2005-10-12 |
| EP1594434B1 (en) | 2016-09-07 |
| EA200501131A1 (ru) | 2006-04-28 |
| US20090169559A1 (en) | 2009-07-02 |
| JP2006517540A (ja) | 2006-07-27 |
| EP1594434A4 (en) | 2008-09-10 |
| ECSP055961A (es) | 2006-04-19 |
| NO20053773D0 (no) | 2005-08-08 |
| US20050008634A1 (en) | 2005-01-13 |
| AU2004206842A1 (en) | 2004-08-05 |
| EA009123B1 (ru) | 2007-10-26 |
| CR7938A (es) | 2006-05-31 |
| US20130023485A1 (en) | 2013-01-24 |
| MXPA05007549A (es) | 2006-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0406745A (pt) | Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico | |
| CN101815724B (zh) | 用于将轭合至其的试剂递送至组织的抑肽酶样多肽 | |
| CA2431600A1 (en) | Molecules with extended half-lives, compositions and uses thereof | |
| DE60141043D1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| JP2011511780A5 (pt) | ||
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| JP2004525922A5 (pt) | ||
| WO2006056464A3 (en) | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) | |
| PE20060817A1 (es) | Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina | |
| HRP20230387T1 (hr) | Farmaceutski pripravci koji sadrže anti-beta amiloidna antitijela | |
| JP5990324B2 (ja) | 生理活性ペプチド複合体 | |
| BR0306838A (pt) | Peptìdeo não-nativo, ácido nucléico isolado, composição farmacêutica e kit para prevenção ou tratamento de uma doença modulada por crf2r | |
| CO5640149A2 (es) | Formulaciones parenterales de un peptido para el tratamiento de lupus sistematico eritematoso | |
| ATE521702T1 (de) | Krebsantigene und deren nutzung | |
| DK0610446T3 (da) | Syntetisk peptidspecificitet af antimyelin basic protein fra cerebrospinalvæske fra dissemineret sklerose | |
| DE69615026D1 (de) | Ein verbessertes peptid, immunogene zusammensetzung und impfstoff oder medizinische präparate, eine methode zur immunisierung von tieren gegen das hormon lhrh und analoge des lhrh-tendem-repeat-peptid und deren verwendung als impfstoff | |
| BRPI0414139A (pt) | métodos e composições para tratar infecções por herpes | |
| IL276911B1 (en) | Variants of the carboxylation rate of antibodies | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| DK0845034T3 (da) | Peptid med pronociceptive egenskaber | |
| AR014884A1 (es) | Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica | |
| US7872098B1 (en) | Phosphorylated derivatives of a U1-70K peptide and their use in the treatment of autoimmune pathologies | |
| WO2014160098A2 (en) | Bordetella specific human recombinant antibodies and uses thereof | |
| JP2005503113A5 (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |